ReViral Ltd develops transformative antiviral therapies, achieving positive results in a Phase IIa RSV challenge study with their RV521 fusion inhibitor, which significantly reduced viral load and symptoms
ReViral Ltd develops transformative antiviral therapies, achieving positive results in a Phase IIa RSV challenge study with their RV521 fusion inhibitor, which significantly reduced viral load and symptoms.